Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Update

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) was the recipient of a large increase in short interest in March. As of March 31st, there was short interest totalling 337,400 shares, an increase of 14.6% from the March 15th total of 294,500 shares. Based on an average daily volume of 169,100 shares, the short-interest ratio is currently 2.0 days. Approximately 2.8% of the company’s stock are sold short.

Acurx Pharmaceuticals Stock Performance

Acurx Pharmaceuticals stock opened at $1.77 on Friday. Acurx Pharmaceuticals has a 52 week low of $1.17 and a 52 week high of $8.82. The stock has a market capitalization of $27.89 million, a P/E ratio of -1.54 and a beta of -1.90. The stock has a 50-day simple moving average of $2.63 and a 200 day simple moving average of $3.37.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings data on Friday, March 15th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.12). Research analysts forecast that Acurx Pharmaceuticals will post -0.97 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered their target price on Acurx Pharmaceuticals from $14.00 to $12.00 and set a “buy” rating for the company in a report on Tuesday, March 19th.

Institutional Investors Weigh In On Acurx Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. NBC Securities Inc. acquired a new stake in Acurx Pharmaceuticals during the first quarter worth approximately $34,000. Sigma Planning Corp acquired a new stake in Acurx Pharmaceuticals during the fourth quarter worth approximately $38,000. BlackRock Inc. lifted its position in Acurx Pharmaceuticals by 149.8% during the first quarter. BlackRock Inc. now owns 16,699 shares of the company’s stock worth $55,000 after acquiring an additional 10,014 shares during the last quarter. Osaic Holdings Inc. lifted its position in Acurx Pharmaceuticals by 37.5% during the second quarter. Osaic Holdings Inc. now owns 22,000 shares of the company’s stock worth $58,000 after acquiring an additional 6,000 shares during the last quarter. Finally, Northern Trust Corp acquired a new stake in Acurx Pharmaceuticals during the fourth quarter worth approximately $66,000. 11.53% of the stock is currently owned by institutional investors and hedge funds.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.